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Animal and Human
Carcinogens
Lewis et al. (1) state that
compared to the fairly large number (> 400) of
known rodent carcinogens, only a relatively small
number of compounds (- 20-30) have been
shown to be carcinogenic in humans.
From this comparison, the authors seem to
infer that animal bioassay cancer findings
overpredict for human carcinogens. Of
course, for most animal carcinogens there
are no available epidemiologic data, and
none planned, or for a few the findings are
either inadequate or of limited value. In
addition, few studies are under way or even
planned on many known and potent animal
carcinogens. Thus, one should realize that
any conclusions about comparative num-
bers between animals and humans that are
based on an apparent absence of data from
humans can only be misleading and basical-
ly unusable for making any meaningful
comparisons. A more relevant correlation to
be made centers on the number of chemi-
cals known to cause cancer in humans that
have also been tested either prospectively or
retrospectively in laboratory animals.
In any event, the numbers reported by
these authors regarding known human car-
cinogens should be updated and modified
using more current information. A pro-
posed updated revision follows.
Utilizing data from the International
Agency for Research on Cancer (IARC
Monographs on the Evaluation ofCarcinogenic
Risks to Humans, volumes 1-73) and the
National Toxicology Program (NTP; Report
on Carcinogens, editions 1-8), there are
approximately 75 agents known to be
causatively associated with cancer in humans
and another 60 considered "probably car-
cinogenic to humans" (Table 1). With few
exceptions, agents in both these categories
have varying evidence of cancer in humans.
While attempting to plan or implement can-
cer prevention strategies, the additional 225
agents considered by IARC as "possibly car-
cinogenic to humans" and the 169 agents
judged by the NTP as "reasonably anticipat-
ed to be carcinogenic to humans" must be
given dose public health attention as well. Of
course both lists must be compared to
account foranyduplications.
I have no particular disagreement with
the number of 400 chemicals as being car-
cinogenic in animals, other than to empha-
size that not all carcinogens are equal. That
is, some chemicals cause multiple site can-
cer in both sexes ofeach strain and species,
whereas others may induce tumors in a sin-
gle organ in one sex of only one strain of
rodent (2). Thus, one must evaluate the
carcinogenicity data for each chemical
rather than simplistically group chemicals
that have been tested into two clusters by
"positive" or "negative" results. In the NTP
for example, ofthe 500 chemicals evaluated
for carcinogenicity,
* 14% caused cancer in each of the four
sex/species groups used for testing
(female rats, male rats, female mice, and
male mice)
* 8% caused cancer in three offour exper-
imental groups
* 18% caused cancer in two offour exper-
imental groups
* 12% caused cancer in one offour exper-
imental groups
* 48% caused cancer in none of four
experimental groups.
Thus, using this data set, roughly 25%
of these 500 (or 125 chemicals) would be
considered as positive in two species, and
therefore meeting established guideline cri-
teria to be evaluated by IARC and/or the
NTP as representing a possible cancer risk
to humans. This does not mean that all 125
chemicals would be listed, only that this
number would be considered for listing. At
this interval, all available data on each agent
must be scrutinized to decide whether the
agent should be to listed or not. If, for the
moment, all 125 were listed, then this
would not be too different from the 135
agents listed by IARC as carcinogenic to
humans or probably carcinogenic to
humans. Interestingly, IARC evaluated
nearly 850 agents and listed only 135 in
these two categories, or 16%, not dissimilar
from that posed by Fung et al. (3).
Consequently one should be more clear
and more precise when using numbers of
chemicals considered to be carcinogenic to
rodents or/and to humans. To designate all
chemicals that induce cancer in animals as
being equal and representing similar and sig-
nificant risks to humans is incorrect and
improper, and should be avoided (4).
Likewise, even though bioassays are indeed
excellent surrogates for humans, not all
chemicals shown to cause tumors in animals
will, or should be expected to, prove to be
carcinogenic to humans. Many reasons can
be given for this lack ofconcordance, but a
main one is that we should not expect the
animal-to-human concordance to be perfect,
largely for the reason mentioned: not all ani-
mal carcinogens are equal (that is, not equal-
ly potent or equally carcinogenic). Thus,
chemicals such as d-limonene orallyl isothio-
cyanate that induce tumors only in the male
rat kidney or urinary bladder are not in
either the IARC or the NTP listings ofcar-
cinogens and clearly do not represent the
likelycancerhazards that than do other more
striking multiorgan, multistrain, and multi-
species carcinogens do. Conversely, we
know that all human carcinogens that have
been tested adequately in animals are also
carcinogenic tolaboratory animals (5).
As shown in Table 1, the NTP has
reviewed more than 800 chemicals as candi-
dates for their Reports on Carcinogens, and
only 198 agents have been judged as
"known to be carcinogenic to humans" (29
agents) or as "reasonably anticipated to be
carcinogenic to humans" (169 agents).
IARC has reviewed and evaluated close to
850 agents in their Monographs program
and found most ofthese (474 agents) inad-
equate for evaluation. Likewise for the
Table 1. Numbers of chemicals (~ 2,000total), groups of chemicals, and exposure circumstances evaluated for carcinogenicity bythe InternationalAgencyfor
Research on Cancer(IARC) and the National Toxicology Program (NTP).
IARC category Chemicals and Biological Exposure circumstances
of evidence Total physical agents agents Mixtures and occupations
IARC evaluationsa(n =833)
Carcinogenic to humans, Group 1 75 39 11 12 13
Probably carcinogenic to humans, Group 2A 59 46 4 5 4
Possibly carcinogenic to humans,Group 2B 227 207 4 12 4
Not classifiable as to its carcinogenicity to humans, Group 3 471 446 6 12 7
Probably not carcinogenic to humans, Group 4 1 1 - - -
Totals 833 739 25 41 28
NTP evaluationsb(n= 800)
Known to be carcinogenic to humans 29
Reasonably anticipated to be carcinogenic to humans 169
Agents or exposure circumstances evaluated and not listedc -600
aData from the IARCMonographs on the Evaluation ofCarcinogenic Risks toHumans, volumes 1-73(International Agencyfor Research on Cancer, Lyon, France). bData from the
Reporton Carcinogens, editions 1-8 (National Toxicology Program, Research Triangle Park, NC}. cConsidered notmeeting guideline criteria as clearlycarcinogenic in two species.
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NTP, many have been considered but few
have been selected. Because many of the
chemicals evaluated by IARC and the NTP
are the same, although many are unique as
well, one cannot simply add numerical data
from these two sources without individual
comparisons. Unfortunately, neither orga-
nization lists the agents that were consid-
ered but not selected for formal review
because the available data are not consid-
ered adequate; that is, there may be no can-
cer data on a chemical, or the available data
are insufficient to meet either agency's crite-
ria for review.
Another issue posed by Lewis et al. (1)
concerns the value ofrodent bioassays. This
has been an ongoing debate for many years.
Some facts may be of interest. We know
that all known human carcinogens that
have been tested adequately in laboratory
rodents are also carcinogenic to animals
(2,4,6); for nearly 30 agents, the evidence of
carcinogenicty was first observed in animals,
ignored for the most part, and only subse-
quently detected in humans (7,8). These
studies have all been accomplished using
what some describe as the "maximum toler-
ated dose," which is at best operational ter-
minology that has been literally misapplied
and distorted, and is obsolete (9,10). A
more accurate term is "minimally toxic
dose" (MTD), or "minimally toxic expo-
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sure" (MTE), because when long-term
bioassays are conducted, one must be cer-
tain that some adverse effects of the chemi-
cal are occurring, or the time, resources,
and efforts will be wasted. Further, there is
little evidence to support a "high-dose only"
phenomenon in carcinogenesis. That is,
using an MTD concept ofexposure cannot
"make" a chemical a carcinogen when it is a
noncarcinogen (1]).
I agree with Lewis et al. (1) that
in the safety evaluation ofchemicals, we should be
cauttiouIs in extrapolating results from experimental
animal Imnodels to humans.
Conversely, I do not agree that we should
ignore long-term bioassay results or delay
preventative strategies until we have defini-
tive mechanistic data, such as, for example,
species differences and similarities in
cytochrome P450 isoform carcinogen
metabolic information, proposed by Lewis
et al. (1). This does not mean such infor-
mation will not be useful to the overall par-
adigm of quantifying carcinogenic risk in
humans, but that equal cautions must be
recognized in considering another in a
lengthy line of mechanistic discoveries.
This information may only modify or
extend quantitative estimates of risk. On
this issue, the distribution ofthese enzymes
may be most useful for evaluating
interindividual differences in susceptibility.
Thus, the public health value and use-
fulness of the bioassay for identifying
potential or likely human carcinogens has a
long history of being quite relevant and
predictive. Perhaps we should give more
attention to these laboratory results when
attempting to prevent human cancers
resulting from exposures to environmental
or occupational carcinogens (12).
James Huff
NIEHS
Research Triangle Park, North Carolina
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In the article by Ritz and Yu ('The
Effect ofAmbient.Carbon'Mobnoxide on
Low Birth. Wei.gbh:t amon.gChildren
Born n :Sou.ithern Californiabetwen
1989` and 1993") pulished in EHP
[107:17-25 (1999)], thei was..an error
in the second sen-tence of the
"Discussion. The satemet "the hemo-
globin in etal bood has 10 tim s more
affinity :for binding CC.)" sol:d read
"he he olbn in ftalbod has 10%t
mo)re affinity for binding CO."
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